IART
INTEGRA LIFESCIENCES HOLDINGS CORP
NASDAQ · Healthcare · Medical - Devices · US
$12.75
−0.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.6B | 1.6B | 1.5B | 1.6B |
| Cost of Revenue | 787.6M | 790.0M | 728.5M | 656.8M | 587.4M |
| Gross Profit | 869.2M | 845.2M | 882.1M | 884.7M | 970.3M |
| Operating Expenses | |||||
| R&D Expense | 94.4M | 99.0M | 115.4M | 104.2M | 101.2M |
| SG&A Expense | 685.2M | 699.7M | 717.0M | 656.6M | 616.3M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (544.9M) | (21.8M) | 21.3M | 12.4M | 13.9M |
| Total Operating Expenses | 234.7M | 776.9M | 853.6M | 773.2M | 731.4M |
| Cost and Expenses | 1.0B | 1.6B | 1.6B | 1.4B | 1.3B |
| Operating Income (EBIT) | 634.5M | 68.3M | 28.4M | 111.5M | 238.9M |
| Non-Operating | |||||
| Interest Income | 14.7M | 18.5M | 20.0M | 17.2M | 11.9M |
| Interest Expense | 96.5M | 86.3M | 70.6M | 51.4M | 49.6M |
| Net Interest Income | (81.8M) | (67.8M) | (50.6M) | (34.2M) | (37.7M) |
| Other Non-Op Income/Expense | (612.2M) | (631.8M) | (46.6M) | (30.5M) | (25.0M) |
| Non-Operating Income (excl Interest) | 515.7M | 545.6M | (24.0M) | (20.9M) | (24.6M) |
| EBT (Pre-Tax Income) | 22.3M | (563.5M) | (18.2M) | 81.1M | 213.9M |
| Income Tax Expense | 9.3M | (47.0M) | (11.3M) | 13.3M | 33.3M |
| Bottom Line | |||||
| Net Income | 13.0M | (516.5M) | (6.9M) | 67.7M | 180.6M |
| Earnings from Cont. Ops | 13.0M | (516.5M) | (6.9M) | 67.7M | 180.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 13.0M | (516.5M) | (6.9M) | 67.7M | 180.6M |
| Per Share | |||||
| Basic EPS | $0.17 | ($6.73) | ($0.09) | $0.87 | $2.18 |
| Diluted EPS | $0.17 | ($6.73) | ($0.09) | $0.84 | $2.16 |
| Revenue Per Share | $21.08 | $21.31 | $20.91 | $19.72 | $18.77 |
| Shares | |||||
| Basic Shares Outstanding | 78.6M | 76.8M | 77.0M | 78.2M | 83.0M |
| Diluted Shares Outstanding | 78.6M | 76.8M | 77.0M | 80.3M | 83.5M |
| Profitability Metrics | |||||
| EBITDA | 233.8M | (325.4M) | 193.3M | 256.0M | 381.8M |
| D&A | 115.0M | 151.8M | 140.9M | 123.5M | 118.3M |
| EBIT | 118.8M | (477.2M) | 52.4M | 132.4M | 263.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026